These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
182 related items for PubMed ID: 832522
21. Fosfomycin in treatment of respiratory bacterial infections. Bonora V, Lozano C, Santos M, Paz M, Baguena J, Gobernado M. Chemotherapy; 1977; 23 Suppl 1():337-41. PubMed ID: 832534 [Abstract] [Full Text] [Related]
22. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Wilson DT, May DB. Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870 [Abstract] [Full Text] [Related]
23. [Clinical trial of fosfomycin for Campylobacter enteritis]. Nogawa T, Takeuchi Y, Watanabe J, Kimura K, Tomii I, Abe T, Watanabe Y, Nakasone K, Fujimori I, Kobayashi Y. Jpn J Antibiot; 1984 Sep; 37(9):1620-4. PubMed ID: 6512981 [Abstract] [Full Text] [Related]
24. [Clinical experience with fosfomycin sodium for bacterial infections in obstetrics and gynecology]. Yamamoto T, Yasuda J, Kanao M, Okada H. Jpn J Antibiot; 1983 Aug; 36(8):2109-14. PubMed ID: 6655828 [Abstract] [Full Text] [Related]
25. [The role of fosfomycin in the management of urinary tract infections]. Zaitsev AV, Kolontarev KB. Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700 [Abstract] [Full Text] [Related]
26. [Clinical experience with fosfomycin in urinary tract infections (author's transl)]. Peters HJ, Eicher R. MMW Munch Med Wochenschr; 1981 May 01; 123(18):748-50. PubMed ID: 6785627 [Abstract] [Full Text] [Related]
27. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H, Hayakawa I, Akimoto T. Yakushigaku Zasshi; 2003 May 01; 38(2):161-79. PubMed ID: 15143768 [Abstract] [Full Text] [Related]
29. [Clinical evaluation of the combination of carumonam and fosfomycin in the treatment of complicated urinary tract infection]. Kakizaki H, Ishii N, Murakami S, Suzuki K, Takamizawa A, Hirano J, Mitobe K, Saito M, Hirano K, Imamura A. Hinyokika Kiyo; 1990 Jun 01; 36(6):731-5. PubMed ID: 2239570 [Abstract] [Full Text] [Related]
30. Treatment of respiratory infections with fosfomycin. Bacardí R, Tornos J, Moga I, Martí N, Alomar P, Gaztelurrutia L, Villalonga C. Chemotherapy; 1977 Jun 01; 23 Suppl 1():343-7. PubMed ID: 832535 [Abstract] [Full Text] [Related]
33. [Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin]. Fujii R, Meguro H, Arimasu O, Ushijima K, Abe T, Nakazawa S, Sato H, Narita A, Niino K, Ichihashi H. Jpn J Antibiot; 1990 Jan 01; 43(1):181-215. PubMed ID: 2190014 [Abstract] [Full Text] [Related]
34. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Traunmüller F, Popovic M, Konz KH, Vavken P, Leithner A, Joukhadar C. Clin Pharmacokinet; 2011 Aug 01; 50(8):493-503. PubMed ID: 21740073 [Abstract] [Full Text] [Related]
37. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Int J Antimicrob Agents; 2009 Dec 01; 34(6):506-15. PubMed ID: 19828298 [Abstract] [Full Text] [Related]
38. Treatment of urinary infections with fosfomycin. Neuman M, Fluteau G. Chemotherapy; 1977 Dec 01; 23 Suppl 1():259-64. PubMed ID: 832524 [Abstract] [Full Text] [Related]